-+ 0.00%
-+ 0.00%
-+ 0.00%

Alzinova Finalizes US Trial Sites for Mid-stage Alzheimer's Disease Vaccine Study

MT Newswires·10/21/2026 06:11:49
Listen to the news
06:11 AM EDT, 10/21/2026 (MT Newswires) -- Alzinova (ALZ.ST) has chosen seven clinical sites in the US for its global phase 2a study of ALZ-101, a vaccine candidate for early Alzheimer's disease. The Advance trial aims to enroll its first participant in late 2026 or early 2027, pending approval of the final protocol amendment and release of clinical trial material, the Swedish biopharmaceutical group said Wednesday. Alzinova also plans to conduct the study in the European Union and the UK.